Journal of Clinical Oncology | 2019
Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC).
Abstract
4039Background: FTD/TPI was approved in 2015 for pretreated pts with mCRC based on the phase 3 RECOURSE trial. FTD/TPI recently demonstrating significantly improved overall survival vs placebo in p...